Print Page | Close Window

Corporate Profile

AtriCure is a medical device company providing innovative solutions designed to decrease the global Afib epidemic.

Stock Quote

ATRC (Common)
PriceChange% ChangeVolume
$18.59 + 0.020.11%240
Previous CloseToday's OpenIntraday HighIntraday Low
$18.57$18.59$18.59$18.59
Exchange: NASDAQ (US Dollar)
03/24/17 9:30 a.m. ET
Minimum 20 minute delay
Refresh quote

Featured Reports

Date
02/28/17
Download Documentation Investor Presentation
10/27/16
Download Documentation Q3 2016 Earnings Call Transcript

All Recent News

DateTitle 
03/21/17AtriCure Names Two New Members to its Board of Directors
MASON, Ohio--(BUSINESS WIRE)--Mar. 21, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that Regina Groves and B. Kristine Johnson have been appointed to its Board of Directors. In addition, the company announced that Michael Hooven and Karen Robards, two existing members of the Board of Directors, will not stand for re-elect... 
Printer Friendly Version
03/14/17AtriCure Names National Principal Investigator for the CONVERGE IDE Clinical Trial
MASON, Ohio--(BUSINESS WIRE)--Mar. 14, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has named Dr. David B. DeLurgio as the national principal investigator (PI) for the CONVERGE IDE clinical trial. Dr. DeLurgio is a cardiac electrophysiologist at Emory Healthcare in Atlanta, GA. He is Director of Electrophysiology... 
Printer Friendly Version
03/10/17AtriCure to Present at the Needham & Company’s 16th Annual Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--Mar. 10, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Needham & Company’s 16th Annual Healthcare Conference at the Westin Grand Central Hotel in New York City on Tuesday, April 4, 2017. Management is scheduled to present at 10:00 a.m. Eastern Time. A live audio webcas... 
Printer Friendly Version
03/06/17AtriCure Announces hiring of Senior Vice President of Clinical, Regulatory, and Scientific Affairs
MASON, Ohio--(BUSINESS WIRE)--Mar. 6, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has hired Vinayak (Vini) Doraiswamy, PhD as its Senior Vice President of Clinical, Regulatory, and Scientific Affairs. Most recently, Dr. Doraiswamy served as Vice President of Global Clinical Operations at St. Jude Medical. In his role... 
Printer Friendly Version
  More News >>

National Recent News

DateTitle 
03/21/17AtriCure Names Two New Members to its Board of Directors
MASON, Ohio--(BUSINESS WIRE)--Mar. 21, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that Regina Groves and B. Kristine Johnson have been appointed to its Board of Directors. In addition, the company announced that Michael Hooven and Karen Robards, two existing members of the Board of Directors, will not stand for re-elect... 
Printer Friendly Version
03/10/17AtriCure to Present at the Needham & Company’s 16th Annual Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--Mar. 10, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Needham & Company’s 16th Annual Healthcare Conference at the Westin Grand Central Hotel in New York City on Tuesday, April 4, 2017. Management is scheduled to present at 10:00 a.m. Eastern Time. A live audio webcas... 
Printer Friendly Version
03/06/17AtriCure Announces hiring of Senior Vice President of Clinical, Regulatory, and Scientific Affairs
MASON, Ohio--(BUSINESS WIRE)--Mar. 6, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has hired Vinayak (Vini) Doraiswamy, PhD as its Senior Vice President of Clinical, Regulatory, and Scientific Affairs. Most recently, Dr. Doraiswamy served as Vice President of Global Clinical Operations at St. Jude Medical. In his role... 
Printer Friendly Version
02/28/17AtriCure Reports Fourth Quarter and Full Year 2016 Financial Results
2016 revenue of $155.1 million – up 19.5% 2016 U.S. sales of $122.4 million – up 19.7% 2016 International sales of $32.7 million – up 18.8% MASON, Ohio--(BUSINESS WIRE)--Feb. 28, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced fourth quarter and full year 2016 financial results. ... 
Printer Friendly Version
  More National News >>

International Recent News

DateTitle 
03/14/17AtriCure Names National Principal Investigator for the CONVERGE IDE Clinical Trial
MASON, Ohio--(BUSINESS WIRE)--Mar. 14, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has named Dr. David B. DeLurgio as the national principal investigator (PI) for the CONVERGE IDE clinical trial. Dr. DeLurgio is a cardiac electrophysiologist at Emory Healthcare in Atlanta, GA. He is Director of Electrophysiology... 
Printer Friendly Version
11/01/16AtriCure Announces Approval for the cryoICE™ Platform in Japan
Approval adds to the growing portfolio of AtriCure products now available in the Japanese market MASON, Ohio--(BUSINESS WIRE)--Nov. 1, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for its cryoICE™ platform and CRYO2 cryoablation ... 
Printer Friendly Version
06/29/16AtriCure Receives CE Mark for the AtriClip® PRO2 Device
CE Mark brings the increased functionality of the AtriClip PRO2 device to the European market for use in managing the left atrial appendage; product was launched in the U.S. in April 2016 MASON, Ohio--(BUSINESS WIRE)--Jun. 29, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has received CE Mark for the AtriClip PRO2 Left ... 
Printer Friendly Version
01/19/16AtriCure Announces Approval for the AtriClip in Japan
Approval opens up a new market for the most widely implanted left atrial appendage occlusion device in the world WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 19, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for its AtriClip™ product... 
Printer Friendly Version
  More International News >>

Company Calendar

DateTitle
04/04/17 
10:00 a.m. ET
AtriCure, Inc. at Needham & Company’s 16th Annual Healthcare Conference
  More Events >>

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.